口服JAK抑制剂联合308nm准分子激光治疗儿童进展期白癜风的多中心研究
这项多中心、前瞻性、单盲随机对照试验纳入188例2至18岁进展期白癜风患儿,治疗48周。A组口服JAK抑制剂联合308nm准分子激光,B组外用他克莫司联合308nm准分子激光。A组复色率显著高于B组(P < .001),不良事件轻至中度且耐受良好。
要点
- 口服JAK抑制剂联合308nm准分子激光可显著提高患儿复色率。
- 不良事件以轻至中度为主,总体耐受性良好。
- 疗效与年龄、病程、皮损部位及毛囊脱色素相关。
核心结论
- 口服JAK抑制剂联合308nm准分子激光治疗儿童进展期白癜风显示出有前景的疗效与安全性,支持其作为潜在治疗选择。
研究设计与样本
- 多中心、前瞻性、单盲随机对照试验,纳入188例2至18岁进展期白癜风患儿,治疗48周。
- A组接受口服JAK抑制剂联合308nm准分子激光治疗,B组接受外用他克莫司联合308nm准分子激光治疗。
- 主要结局为采用白癜风面积评分指数评估的复色率。
主要发现
- A组复色率显著高于B组(P < .001)。
- 不良事件为轻至中度,耐受性良好。
- 治疗反应与年龄、病程、皮损部位及毛囊脱色素相关。
关键数值与推荐
- 主要结局为白癜风面积评分指数评估的复色率,A组显著高于B组(P < .001)。
临床怎么用
- 对于儿童进展期白癜风,可考虑口服JAK抑制剂联合308nm准分子激光作为治疗选项,但需结合年龄、病程、皮损部位及毛囊脱色素情况评估治疗反应。
局限性
- 单盲设计、样本量及随访时间有限、单一对照限制了关于长期疗效与安全性的外推性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment options for progressive vitiligo in children are limited, with current therapies often lacking sustained efficacy and safety. OBJECTIVE: To evaluate the efficacy and safety of Janus kinase inhibitor combined with 308-nm excimer laser therapy in children with progressive vitiligo. METHODS: This multicenter, prospective, single-blind randomized controlled trial enrolled 188 children aged 2∼18 years with progressive vitiligo who received treatment for 48 weeks. Group A received an oral Janus kinase inhibitor combined with 308-nm excimer laser therapy, while Group B received topical tacrolimus combined with 308-nm excimer laser therapy. The primary outcome was the rate of repigmentation assessed by the Vitiligo Area Scoring Index. RESULTS: Group A exhibited significantly higher repigmentation rates than Group B (P < .001), with mild to moderate adverse events and good tolerability. Treatment response was correlated with age, disease duration, lesion location, and follicular depigmentation. LIMITATIONS: The single-blind design, limited sample size and follow-up, and single comparator restrict generalizability regarding long-term efficacy and safety. CONCLUSION: Janus kinase inhibitor combined with 308-nm excimer laser therapy demonstrates promising efficacy and safety in pediatric progressive vitiligo, supporting its potential as a therapeutic option.
引用
- Chang S, Zhang L, Liu B, et al. Efficacy of oral JAK inhibitors combined with 308-nm excimer laser in pediatric progressive vitiligo: A multicenter study. J Am Acad Dermatol. 2026. PMID: 41780599. doi:10.1016/j.jaad.2026.02.096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。